Literature DB >> 12630986

Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population.

Samar I Hamdy1, Masahiro Hiratsuka, Kaori Narahara, Naomi Endo, Mervat El-Enany, Nadia Moursi, Mohammed S-E Ahmed, Michinao Mizugaki.   

Abstract

AIMS: The goal of this study was to determine the frequencies of CYP1A2*1C, *1D, *1E and *1F variants in the Egyptian population and compare frequencies with other populations.
METHODS: Genotyping was performed in a total of 212 unrelated Egyptian subjects using polymerase chain reaction-restriction fragment length polymorphism assay.
RESULTS: The frequencies of CYP1A2*1C, *1D, *1E and *1F variants in the Egyptian population were 0.07, 0.40, 0.03 and 0.68, respectively. The Egyptians have a lower frequency of CYP1A2*1C, and CYP1A2*1E than the Japanese (0.07 vs 0.21 and 0.03 vs 0.08, respectively), while the frequencies of CYP1A2*1D and CYP1A2*1F did not differ significantly between the two groups. CYP1A2*1F (0.68) frequency in Egyptians was identical to that observed in Caucasians (0.68 among 236 German individuals).
CONCLUSIONS: The present study is the first to describe the frequencies of four known allelic variants of CYP1A2 among the Egyptian population. CYP1A2*1C and *1E occurred at frequencies significantly lower than that in Japanese, while similar frequencies were observed for CYP1A2*1D and *1F. The CYP1A2*1F frequency appeared to be identical to that of Caucasians. This does not exclude the possibility of the presence of new mutations relatively specific to the Egyptian population that have not been identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12630986      PMCID: PMC1884219          DOI: 10.1046/j.1365-2125.2003.01787.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.

Authors:  D Sesardic; A R Boobis; R J Edwards; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

2.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.

Authors:  T Coleman; S W Ellis; I J Martin; M S Lennard; G T Tucker
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

3.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.

Authors:  C Sachse; J Brockmöller; S Bauer; I Roots
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

4.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

Authors:  M Nakajima; T Yokoi; M Mizutani; M Kinoshita; M Funayama; T Kamataki
Journal:  J Biochem       Date:  1999-04       Impact factor: 3.387

5.  Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Authors:  Samar Ismail Hamdy; Masahiro Hiratsuka; Kaori Narahara; Mervat El-Enany; Nadia Moursi; Mohammed Salah-Eldin Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

Review 6.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

7.  Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients.

Authors:  W A Anwar; S Z Abdel-Rahman; R A El-Zein; H M Mostafa; W W Au
Journal:  Carcinogenesis       Date:  1996-09       Impact factor: 4.944

8.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.

Authors:  M Nakajima; T Yokoi; M Mizutani; S Shin; F F Kadlubar; T Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994 Jul-Aug       Impact factor: 4.254

9.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

Authors:  M A Butler; N P Lang; J F Young; N E Caporaso; P Vineis; R B Hayes; C H Teitel; J P Massengill; M F Lawsen; F F Kadlubar
Journal:  Pharmacogenetics       Date:  1992-06

10.  Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population.

Authors:  M Chida; T Yokoi; T Fukui; M Kinoshita; J Yokota; T Kamataki
Journal:  Jpn J Cancer Res       Date:  1999-09
  10 in total
  12 in total

1.  Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians.

Authors:  Liliane Todesco; Michael Török; Stephan Krähenbühl; Markus Wenk
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

Review 2.  Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Authors:  Carsten Skarke; Anja Kirchhof; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

3.  PharmGKB summary: very important pharmacogene information for CYP1A2.

Authors:  Caroline F Thorn; Eleni Aklillu; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

4.  Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.

Authors:  Fabiana B Kohlrausch; Ángel Carracedo; Mara H Hutz
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

5.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

Review 6.  Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Authors:  Shu-Feng Zhou; Li-Ping Yang; Zhi-Wei Zhou; Ya-He Liu; Eli Chan
Journal:  AAPS J       Date:  2009-07-10       Impact factor: 4.009

7.  Pharmacogenetics of analgesic drugs.

Authors:  Roman Cregg; Giovanna Russo; Anthony Gubbay; Ruth Branford; Hiroe Sato
Journal:  Br J Pain       Date:  2013-11

8.  Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis.

Authors:  Mohammad M Al-Ahmad; Naheed Amir; Subramanian Dhanasekaran; Anne John; Yousef M Abdulrazzaq; Bassam R Ali; Salim M A Bastaki
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

9.  CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics.

Authors:  Eun-Young Yim; Hye-Ryun Kang; Jae-Woo Jung; Seong-Wook Sohn; Sang-Heon Cho
Journal:  Asia Pac Allergy       Date:  2013-10-31

10.  Investigation of the major cytochrome P450 1A2 genetic variant in a healthy Tibetan population in China.

Authors:  Yongchao Ren; Fang Liu; Xugang Shi; Tingting Geng; Dongya Yuan; Li Wang; Longli Kang; Tianbo Jin; Chao Chen
Journal:  Mol Med Rep       Date:  2017-05-29       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.